Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, AB T6G 1Z2, Canada.
Curr Oncol. 2022 Jan 21;29(2):479-489. doi: 10.3390/curroncol29020043.
Targeting the immune system, especially the PDL-1/PD-1 axis, has significantly improved the outcomes of metastatic lung cancer patients. However, only a portion of patients will benefit significantly from PD(L)1 therapeutics alone or in combination with either chemotherapy or anti-CTLA4 antibody. It is therefore important to study predictive biomarkers to help select the patients who will experience the most benefit from immunotherapy. In this paper, the current status of PDL-1 expression on tumour cells, the smoking status of patients, tumour mutational burden, gut microbiome and STK11 and KEAP1 mutations in the tumour as predictive biomarkers for PD(L)-1-based immunotherapy are summarized.
针对免疫系统，特别是 PD-L1/PD-1 轴，已经显著改善了转移性肺癌患者的预后。然而，只有一部分患者会从 PD(L)1 治疗药物单独或联合化疗或抗 CTLA4 抗体中显著获益。因此，研究预测性生物标志物以帮助选择最能从免疫治疗中获益的患者非常重要。在本文中，总结了肿瘤细胞上 PDL-1 表达、患者吸烟状况、肿瘤突变负担、肠道微生物组以及肿瘤中的 STK11 和 KEAP1 突变作为 PD(L)-1 为基础的免疫治疗的预测性生物标志物的现状。
